Atypical parkinsonism - new advances

Area of Science:

• Neurology
• Genetics
• Pathophysiology

Background:

• Atypical parkinsonism encompasses progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA).
• Recent research has focused on novel genetic factors, disease mechanisms, and potential therapeutic interventions.

Purpose of the Study:

• To review recent advancements in the genetics, pathophysiology, and therapeutic approaches for atypical parkinsonism.
• To highlight key findings from the past two years in the field.

Main Methods:

• Literature review of studies published within the last two years.
• Analysis of genetic associations, pathogenetic mechanisms, and ongoing clinical trials.

Main Results:

• Identification of new risk loci for PSP and CBD, with ongoing investigation into their pathogenic roles.
• Continued debate on COQ2 variants in MSA, alongside evidence of coenzyme Q10 deficiency.
• The prion hypothesis gaining traction in pathogenesis research, with early-phase clinical trials initiated.
• Persistent challenges in clinical diagnosis and recognition of significant phenotypic variability.
• Numerous studies are actively evaluating potential neuroprotective agents.

Conclusions:

• Significant progress has been made in understanding the genetics and pathophysiology of atypical parkinsonism.
• The field is moving closer to identifying effective neuroprotective treatments for these debilitating conditions.